Affiliation:
1. Department of Immunization Program Zhejiang Provincial Center for Disease Control and Prevention Hangzhou China
2. School of Public Health Xiamen University Xiamen China
3. Department of Microbiology Zhejiang Provincial Center for Disease Control and Prevention Hangzhou China
4. Department of AIDS and STD Control and Prevention Zhejiang Provincial Center for Disease Control and Prevention Hangzhou China
5. Department of Viral Hepatitis National Institute for Viral Disease Control and Prevention, China CDC Beijing China
Abstract
AbstractIn 2020, China conducted a nationwide, sero‐epidemiological, cross‐sectional survey of viral hepatitis. The stratified multi‐stage cluster random sampling method was used to select the permanent population aged 1–69 years, followed by questionnaire survey and sample collection and detection of the serological markers of hepatitis B (HBV) and hepatitis C viruses (HCV). A total of 4747 individuals aged 1–69 years were investigated in Zhejiang Province. The positive rates of hepatitis B surface antigen and anti‐HCV were 4.3% and 0%, respectively. Compared to a similar sero‐epidemiological survey in 1992, the 2020 survey showed that the HBV infection rate in Zhejiang Province decreased by 56.5%. In both surveys, HBV infection rate increased with age (in 1992, χ2 = 185.866, p = .000; in 2020, χ2 = 1383.836, p = .000). Compared with 1992, the positive anti‐HCV rate in those aged 1–69 years in 2020 decreased by 100.0%. This result showed that the HBV vaccine and blood screening to prevent HBV and HCV infection significantly decreased the infection rate of HBV and HCV in the younger generation of Zhejiang province. However, the rate of HBV carriers aged 30–69 years was still high, which underscores the need to strengthen the management and treatment of chronic HBV infection. Hence, Zhejiang province can eliminate the public health threat of viral hepatitis.
Subject
Virology,Infectious Diseases,Hepatology
Reference40 articles.
1. WHO.Hepatitis. Accessed November 9 2022.https://www.who.int/health‐topics/hepatitis#tab=tab_1
2. WHO.Interim guidance for country validation of viral hepatitis elimination. Accessed November 9 2022.https://www.who.int/publications/i/item/9789240028395
3. Countdown to 2030: eliminating hepatitis B disease, China
4. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy
5. Trends in the disease burden of HBV and HCV infection in China from 1990-2019
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献